The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! About 3.28 million shares traded hands or 2.82% up from the average. Horizon Pharma PLC (NASDAQ:HZNP) has risen 33.23% since April 27, 2016 and is uptrending. It has outperformed by 28.00% the S&P500.
The move comes after 5 months negative chart setup for the $3.17 billion company. It was reported on Nov, 30 by Barchart.com. We have $18.29 PT which if reached, will make NASDAQ:HZNP worth $221.90M less.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on March, 6. They expect $0.52 earnings per share, 0.00% or $0.00 from last year’s $0.52 per share. HZNP’s profit will be $83.80 million for 9.46 P/E if the $0.52 EPS becomes a reality. After $0.56 actual earnings per share reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Horizon Pharma has been the topic of 21 analyst reports since September 9, 2015 according to StockzIntelligence Inc. On Tuesday, May 3 the stock rating was maintained by Mizuho with “Buy”. Mizuho maintained the shares of HZNP in a report on Tuesday, September 13 with “Buy” rating. The firm earned “Buy” rating on Tuesday, January 19 by Jefferies. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) rating on Monday, December 14. Mizuho has “Buy” rating and $36 price target. The company was initiated on Wednesday, June 29 by BMO Capital Markets. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) rating on Monday, October 31. Mizuho has “Buy” rating and $29 price target. The firm has “Buy” rating by Goldman Sachs given on Thursday, December 17. Morgan Stanley reinitiated it with “Underweight” rating and $23.0 target price in Thursday, December 3 report. Citigroup maintained it with “Neutral” rating and $21 target price in Tuesday, August 9 report. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Market Perform” rating by Cowen & Co on Friday, September 16.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.46 in 2016 Q2. Its up 0.25, from 1.21 in 2016Q1. The ratio improved, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Rhenman Prtn Asset Management last reported 1.08% of its portfolio in the stock. Turner Invests Ltd Partnership has 0.37% invested in the company for 71,420 shares. Proshare Advisors Limited Liability owns 143,939 shares or 0.03% of their US portfolio. Artal Gru Sa reported 350,000 shares or 0.12% of all its holdings. Alliancebernstein Limited Partnership accumulated 0% or 262,160 shares. Nomura Inc accumulated 20,690 shares or 0% of the stock. Hodges Capital Mngmt accumulated 1.75% or 2.19 million shares. Raymond James Assocs has 166,881 shares for 0.01% of their US portfolio. First Manhattan owns 16,297 shares or 0% of their US portfolio. Moody Natl Bank Division holds 18,265 shares or 0.02% of its portfolio. Kcg Holdings last reported 0.01% of its portfolio in the stock. Moreover, Oppenheimer And has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 16,697 shares. Armistice Ltd Llc holds 400,000 shares or 2.51% of its portfolio. Emerald Advisers Pa reported 204,797 shares or 0.16% of all its holdings. Moreover, National Bank & Trust Of Montreal Can has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 618,861 shares.
Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 insider sales for $500,280 net activity. The insider SHERMAN JEFFREY W sold $58,000. Nohria Virinder sold $442,280 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Wednesday, June 15.
More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016. Also Fool.com published the news titled: “Why Allergan, Horizon Pharma plc, and Pfizer All Spiked Wednesday” on November 10, 2016. Seekingalpha.com‘s news article titled: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” with publication date: November 07, 2016 was also an interesting one.
HZNP Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.